Misao Fujita

MS, MPH, PhD
Head, Professor
Field:Medical ethics, Clinical psychology

Institute for the Advanced Study of Human Biology
Professor
ASHBi website

Message

iPS Cell is a leading-edge life science technology that was originally developed in Japan. We believe it is the responsibility of Japanese researchers to study ethical, legal, and social issues (ELSI) related to its clinical application and publish the results internationally. Drawing on all of the knowledge I have acquired on medical ethics, research skills, and clinical experiences, I am committed to developing the Uehiro Research Division for iPS Cell Ethics as a hub for ELSI research on iPS cells.

Biography

1992 Graduated from the College of Human Sciences, University of Tsukuba
1995 M.A. in Clinical psychology, The University of Idaho
1995 Clinical psychologist, Obitsusankei hospital
2003 MPH, Graduate School of Medicine, Kyoto University
2004 Researcher in Center for Biomedical Ethics and Law,
          Graduate School of Medicine, Tokyo University
2006 Ph.D in Public Health, Graduate School of Medicine, Kyoto University
2008 Project Assistant professor in Department of Biomedical Ethics,
          Graduate School of Medicine, Tokyo University
2009 Assistant professor in Department of Biomedical Ethics,
          Graduate School of Medicine, Tokyo University
2013 Project Associate Professor, Uehiro Research Division for iPS Cell Ethics,
          Center of iPS Cell Research and Application
2018 Project Professor, Uehiro Research Division for iPS Cell Ethics,
          Center of iPS Cell Research and Application
          Professor, Institute for the Advanced Study of Human Biology

Position

  • International Bioethics Committee, UNESCO (Member, 2018-)
  • Japanese National Commission for UNESCO (Member ,2018-)
  • BioBank Japan, Advisory Board (Member 2018-)
  • Expert Panel on Bioethics, the Cabinet Office’s Council for Science, Technology and Innovation (Member, 2017-)
  • Task Force for Revision of the Report on Fundamental Policy on Handling of Human Embryos, Expert Panel on Bioethics, the Cabinet Office’s Council for Science, Technology and Innovation (Member, 2017-)
  • The Ministry of Education, Culture, Sports, Science and Technology (Advisor, participated in the IGBC of UNESCO, June 17-22, 2017; participated in IBC/COMEST of UNESCO, September 11-15, 2017)
  • Japan Association for Bioethics (Councilor, 2017-)
  • International Society for Stem Cell Research (Ethics Committee Member, 2016-)

Research activities

Selected publications

  1. Ide K, Koshiba H, Hawke P, Fujita M. Guidelines are urgently needed for the use of preprints as a source of information. J Epidemiol. 2020, in press. DOI: 10.2188/jea.JE20200506.
  2. Crane AT, Shen FX, Brown JL, Cormack W, Ruiz-Estevez M, Voth JP, Sawai T, Hatta T, Fujita M, Low WC. The American public is ready to accept human-animal chimera research. Stem Cell Reports. 2020. DOI: 10.1016/j.stemcr.2020.08.018.
  3. Sawai T, Minakawa T, Pugh J, Akatsuka K, Yamashita JK, Fujita M. The moral status of human embryo‐like structures: potentiality matters?. EMBO Reports. 2020; 20(8): 32-36. DOI: 10.1080/15265161.2020.1782524.
  4. Sawai T, Sakaguchi H,Thomas E, Takahashi J, Fujita M. The ethics of cerebral organoid research: Being conscious of consciousness. Stem Cell Reports 13(3): 440-447. DOI: 10.1016/j.stemcr.2019.08.003.
  5. Ozeki-Hayashi R, Fujita M, Tsuchiya A, Hatta T, Nakazawa E, Takimoto Y, Akabayashi A. Beliefs held by breast surgeons that impact the treatment decision process for advanced breast cancer patients: a qualitative study. Breast Cancer: Targets and Therapy. 2019; 11: 221-229. DOI: https://doi.org/10.2147/BCTT.S208910.
  6. Sawai T, Hatta T, Fujita M. Japan significantly relaxes its human-animal chimeric embryo research regulations. Cell Stem Cell. 2019 (in press).
  7. Fujita M, Keiichi Tabuchi. A rebuttal to Akabayashi and colleagues’ criticisms of the iPSC stock project. Journal of Medical Ethics. 2019; DOI: 10.1136/medethics-2018-105248.
  8. Sawai T, Hatta T, Fujita M. The Japanese generally accept human-animal chimeric embryo research but are concerned about human cells contributing to brain and gametes. Stem Cells Translational Medicine. 2017; DOI: 10.1002/sctm.17-0128.
  9. Sawai, T., Hatta, T., and Fujita M. 2017. “Public attitudes in Japan towards human-animal chimeric embryo research using human induced pluripotent stem cells.” Regenerative Medicine, DOI: 10.2217/rme-2016-0171.
  10. Takashima K, Takimoto Y, Nakazawa E, Hayashi Y, Tsuchiya A, Fujita M, Akabayashi A. Discovery and informing study participants of incidental findings detected in brain magnetic resonance imaging studies: review and multi-institutional study. Brain and Behavior. 2017; DOI: 10.1002/brb3.676.
  11. Sawai T, Fujita M. The Problem of Dual Use in Relation to Decoded Neurofeedback. AJOB Neuroscience. 2016; 7(4): W4-W5. DOI: 10.1080/21507740.2016.1244126.
  12. Kashihara H, Nakayama T, Hatta T, Takahashi N, Fujita M. Evaluating the quality of website information on private-practice clinics offering cell therapies in Japan. interactive Journal of Medical Research. 2016; 5(2):e15. DOI: 10.2196/ijmr.5479
  13. Fujita M, Hatta T, Reina O, Akabayashi A. The current status of clinics providing private practice cell therapy in Japan. Regenerative Medicine 2016;11(1):23-32.
  14. Takahashi S, Fujita M, Akabayashi A. “Mottainai” embryos and the earthquake. J Clin Res Bioeth. 2015;7:258
  15. Ikka T, Fujita M, Yashiro Y, Ikegaya H. Recent Court Ruling in Japan Exemplifies Another Layer of Regulation for Regenerative Therapy. Cell Stem Cell 2015; 17(5): 507-508.
  16. Fujita M, Hatta T, Sawai T, Takahashi J. Risk of Tumorigenesis and Patient Hope. AJOB Neuroscience 2015; 6: 69-70.
  17. Fujita M, Hayashi Y, Tashiro S, Takashima K, Nakazawa E, Akabayashi A. Handling incidental findings in neuroimaging research in Japan: current state of research facilities and attitudes of investigators and the general population. Health Research Policy and Systems 2014; 12: 58.
  18. Fujita M, Yashiro Y, Suzuki M. Throwing the baby out with the bathwater: a critique of Sparrow’s inclusive definition of the term ‘in vitro eugenics.’ J Med Ethics. 2013 Aug 28.
  19. Akabayashi A, Fujita M. The present and future of stem cell therapy in Japan. In: Uehiro T (ed). Ethics for the Future of Life, 9-19. Oxford Uehiro Center for Practical Ethics; 2013.
  20. Takahashi S, Fujita M, Fujimoto A, Fujiwara T, Yano T, Tsutsumi O, Taketani Y, Akabayashi A. The decision-making process for the fate of frozen embryos by Japanese infertile women: a qualitative study. BMC Medical Ethics 2012; 13: 9.
  21. Fujita M, Matsui K, Monden M, Akabayashi A. Attitudes of medical professionals and transplant facilities toward living donor liver transplantation in Japan. Transplantation Proceedings 2010; 42: 1453-9.
  22. Fujita M, Slingsby BT, Akabayashi A. Transplant tourism from Japan. American Journal of Bioethics 2010; 10(2): 24-6.
  23. Fujita M, Kodama S, Akabayashi A. Ten years after the organ transplant act: Current situation in Japan. IAB News 2008; 20: 5.
  24. Nagao N, Aulisio MP, Nukaga Y, Fujita M, Kosugi S, Youngner S, Akabayashi A. Clinical Ethics Consultation: Examining how American and Japanese experts analyze an Alzheimer’s case. BMC Med Ethics 2008; 9: 2.
  25. Fujita M, Akabayashi A, Slingsby BT, Kosugi S, Fujimoto Y, Tanaka K. A model of donors’ decision-making in adult-to-adult living donor liver transplantation in Japan: having no choice. Liver Transplantation 2006;12:768-774.
  26. Fujita M, Slingsby BT, Akabayashi A: Three patterns of voluntary consent in the case of adult-to-adult living related liver transplantation in Japan. Transplantation Proceedings 2004:36;1425-1428.
  27. Akabayashi A, Fujita M, Slingsby BT: The first donor death of living related liver transplantation in Japan. Transplantation 2004;77:634.
  28. Akabayashi A, Nishimori M, Fujita M, Slingsby BT: Living related liver transplantation: A Japanese experience and development of a checklist for donors’ informed consent. Gut 2003;52:152.